dc.contributor.author | Prevet, H | |
dc.contributor.author | Collins, I | |
dc.date.accessioned | 2019-03-18T11:15:51Z | |
dc.date.issued | 2019-05-24 | |
dc.identifier.citation | Future medicinal chemistry, 2019, 11 (10), pp. 1195 - 1224 | |
dc.identifier.issn | 1756-8919 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3158 | |
dc.identifier.eissn | 1756-8927 | |
dc.identifier.doi | 10.4155/fmc-2018-0370 | |
dc.description.abstract | Demonstrating target engagement in living systems can help drive successful drug discovery. Target engagement and occupancy studies in cells confirm direct binding of a ligand to its intended target protein and provide the binding affinity. Combined with biomarkers to measure the functional consequences of target engagement, these experiments can increase confidence in the relationship between in vitro pharmacology and observed biological effects. In this review, we focus on chemically and radioactively labelled probes as key reagents for performing such experiments. Using recent examples, we examine how the labelled probes have been employed in combination with unlabelled ligands to quantify target engagement in cells and in animals. Finally, we consider future developments of this emerging methodology. | |
dc.format | Print | |
dc.format.extent | 1195 - 1224 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | FUTURE SCI LTD | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | |
dc.subject | Animals | |
dc.subject | Humans | |
dc.subject | Fluorescent Dyes | |
dc.subject | Drug Evaluation, Preclinical | |
dc.subject | Drug Discovery | |
dc.subject | Molecular Targeted Therapy | |
dc.subject | Optical Imaging | |
dc.title | Labelled chemical probes for demonstrating direct target engagement in living systems. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2019-01-29 | |
rioxxterms.versionofrecord | 10.4155/fmc-2018-0370 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | |
rioxxterms.licenseref.startdate | 2019-05 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Future medicinal chemistry | |
pubs.issue | 10 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 2 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 2 | |
pubs.publication-status | Published | |
pubs.volume | 11 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Medicinal Chemistry 2 | |
dc.contributor.icrauthor | Prevet, Hugues | |
dc.contributor.icrauthor | Collins, Ian | |